{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:55:55Z","timestamp":1740174955291,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The therapeutic landscape for ulcerative colitis (UC) has recently broadened to include anti-TNF\u03b1, anti-integrin, and anti-IL-12\/23p40 antibody agents. These biological agents are tailored to individual patient profiles. However, some patients cease biological treatment. This study investigates factors influencing the discontinuation of biological treatment in UC patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective single-cohort study encompasses UC patients who commenced treatment with biological agents like infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab from April 2019 to March 2022. Patients were categorized into continuation and discontinuation groups based on their one-year treatment status. Baseline characteristics were compared between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 116 UC patients, 102 were included in the study. Among these, 74 (72.5%) continued and 28 (27.5%) discontinued biological therapy. Discontinuation rates for infliximab, adalimumab, golimumab, vedolizumab, and ustekinumab were 33.3%, 25.0%, 50.0%, 30.2%, and 15.6%, respectively. The primary discontinuation reason was lack of efficacy (85.7%), followed by adverse events (7.1%), pregnancy (3.6%), and death (3.6%). The discontinuation group had a significantly lower rate of concomitant thiopurine compared to the continuation group (28.6% <jats:italic>vs<\/jats:italic>. 56.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0132). Multivariable analysis revealed that concomitant thiopurine was independently associated with therapy continuation (<jats:italic>p<\/jats:italic>\u2009=\u20090.0075).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study indicates that concomitant thiopurine significantly correlates with the continuation of biological therapies in UC patients, underscoring the importance of concomitant thiopurine in sustaining biological therapy. Further studies are warranted to assess the efficacy of combination therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00386-2","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:02:56Z","timestamp":1729263776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis"],"prefix":"10.1186","volume":"10","author":[{"given":"Arisa","family":"Fukuyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4526-3045","authenticated-orcid":false,"given":"Motoyasu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hisabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Imakyure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"386_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u201384.","journal-title":"Lancet"},{"key":"386_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"key":"386_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"386_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"386_CR5","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"386_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Van Assche G, Reinisch W, Colombel JF, D\u2019Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.e1.","journal-title":"Gastroenterology"},{"key":"386_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85\u201395 quiz e14.","journal-title":"Gastroenterology"},{"key":"386_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96-109.e1.","journal-title":"Gastroenterology"},{"key":"386_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"386_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"386_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","volume":"21","author":"K Papamichael","year":"2015","unstructured":"Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182\u201397.","journal-title":"Inflamm Bowel Dis"},{"key":"386_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/apt.16060","volume":"52","author":"EV Loftus Jr","year":"2020","unstructured":"Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1353\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"386_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","volume":"16","author":"MT Abreu","year":"2022","unstructured":"Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022;16:1222\u201334.","journal-title":"J Crohns Colitis"},{"key":"386_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","volume":"10","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Rivals-Lerebours O, Billiet T, VandeCasteele N, Gils A, Ferrante M, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis. 2016;10:1015\u201323.","journal-title":"J Crohns Colitis"},{"key":"386_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","volume":"146","author":"R Panaccione","year":"2014","unstructured":"Panaccione R, Ghosh S, Middleton S, M\u00e1rquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3.","journal-title":"Gastroenterology"},{"key":"386_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"386_CR17","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1097\/MD.0000000000001513","volume":"94","author":"Y Qiu","year":"2015","unstructured":"Qiu Y, Mao R, Zhang S-H, Li M-Y, Guo J, Chen B-L, et al. Safety profile of thiopurines in Crohn disease: Analysis of 893 patient-years follow-up in a Southern China cohort. Medicine (Baltimore). 2015;94:e1513.","journal-title":"Medicine (Baltimore)"},{"key":"386_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"S-K Yang","year":"2014","unstructured":"Yang S-K, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46:1017\u201320.","journal-title":"Nat Genet"},{"key":"386_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53:1065\u201378.","journal-title":"J Gastroenterol"},{"key":"386_CR20","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.cgh.2020.07.012","volume":"19","author":"A Hu","year":"2021","unstructured":"Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol. 2021;19:1366-1376.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"386_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"386_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, VandeCasteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis. J Crohns Colitis. 2018;12:635\u201343.","journal-title":"J Crohns Colitis"},{"key":"386_CR23","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68:814\u201328.","journal-title":"Gut"},{"key":"386_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ibd\/izab117","volume":"28","author":"M Gazouli","year":"2022","unstructured":"Gazouli M, Dovrolis N, Bourdakou MM, Gizis M, Kokkotis G, Kolios G, et al. Response to anti-\u03b14\u03b27 blockade in patients with ulcerative colitis is associated with distinct mucosal gene expression profiles at baseline. Inflamm Bowel Dis. 2022;28:87\u201395.","journal-title":"Inflamm Bowel Dis."},{"key":"386_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/apt.15706","volume":"51","author":"H Alric","year":"2020","unstructured":"Alric H, Amiot A, Kirchgesner J, Tr\u00e9ton X, Allez M, Bouhnik Y, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948\u201357.","journal-title":"Aliment Pharmacol Ther"},{"key":"386_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/apt.15745","volume":"52","author":"VB Biemans","year":"2020","unstructured":"Biemans VB, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, L\u00f6wenberg M, de Boer NK, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn\u2019s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123\u201334.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00386-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:13:59Z","timestamp":1729264439000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00386-2","relation":{},"ISSN":["2055-0294"],"issn-type":[{"type":"electronic","value":"2055-0294"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects. Patient consent was waived due to the retrospective design of the study. In this study, we used the opt-out method. The disclosure document for this clinical study was provided through the Fukuoka University website. The study was approved by Fukuoka University-Medical Ethics review board (C24-01\u2013003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}